how i select patients for lutetium-psma radioligand therapy
Published 8 months ago • 6.1K plays • Length 12:36Download video MP4
Download video MP3
Similar videos
-
15:35
lu-psma radioligand therapy
-
1:10:05
psma scans & pluvicto (lutetium-177) in 2022 | geoffrey johnson, md, phd | pcri conference 2022
-
1:22
treatment for advanced prostate cancer patients | lutetium 177 psma radioligand therapy | mercy
-
2:56
psma pet ratio predicts response to [177lu]psma radioligand therapy: a multicenter study
-
1:27:12
personalized cancer therapy: using psma radioligand therapy of metastatic prostate cancer
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
4:28
upfront [177lu]lu-psma-617 radioligand therapy prior to radical prostatectomy in men with hr pc
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
1:27:31
new era of lutetium-psma post approval: perspectives, challenges & future
-
1:23:01
bringing lutetium psma earlier: with perspectives from asia
-
14:37
lupsma: the newest treatment class for advanced prostate cancer
-
6:51
psma pet/ct “live” cases: pearls and pitfalls - mdt panel @ prostic preceptorship 2022 preview
-
19:50
eanm2020 - dosimetry and radiobiology of lu psma treatment whole body tumour dose by dr john violet
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
0:16
lutetium-177 psma therapy
-
1:50
cat 3: psma radioligand therapy (prlt) of end-stage prostate cancer patients selected by psma pet/ct
-
17:05
psma targeting for treatment of advanced prostate cancer - 2021 prostate cancer patient conference
-
10:43
appropriate use of psma pet in clinical practice
-
1:16
chapter 4: what it's like to have 177 lutetium psma therapy